Late Anthracycline-Related Cardiotoxicity in Low-Risk Breast Cancer Patients

Anthracyclines improve survival in breast cancer, but can cause cardiotoxicity, manifest either as overt clinical heart failure or asymptomatic left ventricular dysfunction. Determining cardiotoxicity prevalence is difficult; definitions vary, presentation may be delayed, and risk varies by